Status:

COMPLETED

Supplementation of YMETA, on Gut Health, Immunity and Metabolism in Pre-diabetic Adult Population

Lead Sponsor:

University of Roehampton

Collaborating Sponsors:

Vemico Ltd.

Conditions:

Pre-diabetes

Eligibility:

All Genders

18-60 years

Phase:

NA

Brief Summary

Type 2 diabetes mellitus (T2DM) is a major non-communicable disease and one of the world's fastest growing health problems. According to a 2019 report, about 463 million adults worldwide currently hav...

Detailed Description

Y META is a combination of gut health focused bioactives that target both the metabolic activity of existing microbiota (Bifidobacterium spp. targeting prebiotic galacto-oligosaccharides mixture) and ...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Adults aged between 18 and 60 years, with
  • Fasting blood glucose level of 5.6-6.9mmol/L or
  • Impaired HbA1c (HbA1c level of 5.7%-6.4%)
  • For intervention purposes, eligible participants are also required to have a mobile phone and be able to read and speak English.
  • Exclusion criteria
  • People with a current diagnosis or clinical history of T2DM
  • People with comorbid conditions that may limit participation in the study, such as a history of an acute cardiovascular event, uncontrolled hypertension, cancer or major psychiatric or cognitive problems
  • People who are already participating in a weight loss programme
  • People receiving drug treatment for pre-diabetes (eg, metformin)
  • People with a history of long-term use of medicines known to influence glucose metabolism (eg, corticosteroids)
  • People with elevated liver enzymes (alanine aminotransferase ≥300 IU/L, aspartate aminotransferase ≥300 IU/L)
  • People who take antibiotics or bacterial agents (Probiotics) within 1 month
  • Pregnant women, women ready for pregnancy, and nursing mothers

Exclusion

    Key Trial Info

    Start Date :

    June 15 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    September 20 2023

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT05400525

    Start Date

    June 15 2022

    End Date

    September 20 2023

    Last Update

    November 15 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Health Sciences Research Centre, Life Sciences Department, University of Roehampton

    London, UK, United Kingdom, SW15 4JD